Nivolumab Plus Relatlimab: First Approval
Year: 2022
Type: article
Source: Drugs
Author: Julia Paik
Institution: Springer Nature (New Zealand)
Language: French
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4280599663
